Archives of Iranian medicine · 2026
Comparison in Patients' Adherence, Adverse Effects, and Clinical Outcomes Among Liver Transplant Recipients Using Immediate-Release Tacrolimus (Prograf®) Versus Extended-Release Tacrolimus (Advagraf®): First Report from Iran.
СтатьяНаблюдательное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shafiekhani Mojtaba, Mahmoudi Mohamad Mahdi, Rostami Hasan, Shamsaeefar Alireza, Sohrabi Nazari Sahar, Doostfatemeh Marziyeh, Alishavandi Fatemeh, Rajabian Mohamad Sadegh, Nikoupour Hamed
Аннотация
INTRODUCTION: Medication adherence is a crucial factor in liver transplant patients' improvement of quality of life and survival rates and reduction of allograft rejection. Tacrolimus plays a pivotal role in post-transplant immunosuppressive therapy, which is available both as twice-daily immediate-release tacrolimus (Prograf®) and once-daily extended-release tacrolimus (Advagraf®). This study compared adherence, adverse effects, and clinical outcomes between patients using once-daily extended-release tacrolimus (ERT; Advagraf®) and twice-daily immediate-release tacrolimus (IRT; Prograf®) in a real-world setting.
METHODS: This prospective observational study involved eligible adult liver transplant recipients at least six months post-transplant, prescribed either Prograf® or Advagraf® as part of their immunosuppressive regimen. The primary outcome was the change in adherence from baseline to six months. Patient adherence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS) at baseline and 6 months. The dose-to-concentration ratio of tacrolimus, potential side effects, and intra-patient variability were assessed at baseline and at one-month and six-month follow-ups. Data were collected through face-to-face interviews, medical records review, pharmacy database exploration, and phone surveys.
RESULTS: Baseline adherence was similar between the groups (Prograf® 48.5% vs. Advagraf® 41.2%, P=0.39). At six months, the ERT (Advagraf®) group was associated with higher adherence rates in adjusted analysis (Adjusted Odds Ratio [AOR]: 2.5, 95% CI: 1.1-5.8). Factors significantly associated with higher adherence included older age (AOR: 1.05 per year, 95% CI: 1.01-1.09) and shorter time since transplant (AOR: 0.98 per month, 95% CI: 0.97-0.99). The ERT group also reported a lower incidence of hand tremors (15% vs. 32%, P=0.015). Trough levels, dose/concentration ratios, and renal function were comparable.
CONCLUSION: In this observational study, the once-daily Advagraf® formulation was associated with significantly better medication adherence and a lower reported incidence of tremors compared to twice-daily Prograf®. These findings should be interpreted in the context of the study's non-randomized design and potential confounding.
METHODS: This prospective observational study involved eligible adult liver transplant recipients at least six months post-transplant, prescribed either Prograf® or Advagraf® as part of their immunosuppressive regimen. The primary outcome was the change in adherence from baseline to six months. Patient adherence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS) at baseline and 6 months. The dose-to-concentration ratio of tacrolimus, potential side effects, and intra-patient variability were assessed at baseline and at one-month and six-month follow-ups. Data were collected through face-to-face interviews, medical records review, pharmacy database exploration, and phone surveys.
RESULTS: Baseline adherence was similar between the groups (Prograf® 48.5% vs. Advagraf® 41.2%, P=0.39). At six months, the ERT (Advagraf®) group was associated with higher adherence rates in adjusted analysis (Adjusted Odds Ratio [AOR]: 2.5, 95% CI: 1.1-5.8). Factors significantly associated with higher adherence included older age (AOR: 1.05 per year, 95% CI: 1.01-1.09) and shorter time since transplant (AOR: 0.98 per month, 95% CI: 0.97-0.99). The ERT group also reported a lower incidence of hand tremors (15% vs. 32%, P=0.015). Trough levels, dose/concentration ratios, and renal function were comparable.
CONCLUSION: In this observational study, the once-daily Advagraf® formulation was associated with significantly better medication adherence and a lower reported incidence of tremors compared to twice-daily Prograf®. These findings should be interpreted in the context of the study's non-randomized design and potential confounding.